A French Multicenter Open Label Phase 4 Extension Study of Long-term Safety and Efficacy in Patients With Pompe Disease Who Previously Participated in Avalglucosidase Alfa Development Studies in France

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 04 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avalglucosidase alfa (Primary)
Indications Glycogen storage disease type II
Focus Adverse reactions
Acronyms PTA Avalglucosidase
Sponsors Sanofi Genzyme; Sanofi-Aventis Recherche & Developpement

Most Recent Events

31 Jan 2025 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
31 Jan 2025 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.
04 Aug 2023 Planned End Date changed from 5 Jan 2025 to 31 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight